Tyme Technologies, Inc. (NasdaqCM:TYME) will look for acquisitions. On February 8, 2021, the Company closed on a registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share. The gross proceeds of the offering were $100 million, prior to deducting placement agent's fees and other offering expenses payable by TYME, which were approximately $6.2 million. The Company intends to continue to use the net proceeds of this offering for the development of clinical and preclinical assets and for general corporate purposes, capital expenditures, working capital and general and administrative expenses. It may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to own, although it has no current plans, commitments or agreements with respect to any acquisitions.